Skip to main content

ADVERTISEMENT

outcomes research

News
06/01/2020
On the first day of the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30, 2020), Helen MacKay, MBChB, BSc, MRCP, MD, department of medicine, University of Toronto, provided the context and...
On the first day of the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30, 2020), Helen MacKay, MBChB, BSc, MRCP, MD, department of medicine, University of Toronto, provided the context and...
On the...
06/01/2020
Journal of Clinical Pathways
News
05/21/2020
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
...
05/21/2020
Journal of Clinical Pathways
News
05/14/2020
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or...
05/14/2020
Journal of Clinical Pathways
News
08/22/2017
JCP Editors
A recent comparative effectiveness study examined long-term survival outcomes for patients with multiple stages of breast cancer after undergoing either mastectomy or breast-conserving surgery, published in the...
A recent comparative effectiveness study examined long-term survival outcomes for patients with multiple stages of breast cancer after undergoing either mastectomy or breast-conserving surgery, published in the...
A...
08/22/2017
Journal of Clinical Pathways
Research in Review
08/18/2017
JCP Editors
A recent study uncovered the benefits of adding high-intensity local treatment to systemic therapy for head and neck squamous cell carcinoma, published in Cancer (online August 17, 2017;...
A recent study uncovered the benefits of adding high-intensity local treatment to systemic therapy for head and neck squamous cell carcinoma, published in Cancer (online August 17, 2017;...
A...
08/18/2017
Journal of Clinical Pathways
Research in Review
08/18/2017
JCP Editors
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL). Rituximab plus cyclophosphamide,...
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL). Rituximab plus cyclophosphamide,...
A...
08/18/2017
Journal of Clinical Pathways
Author Insights
08/14/2017
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a...
08/14/2017
Journal of Clinical Pathways
Research in Review
08/14/2017
JCP Editors
A recent study suggests a variable that should be used as a standard outcome measure for clinical trials of patients with follicular lymphoma, published in the British Journal of Hematology (online August 7, 2017;...
A recent study suggests a variable that should be used as a standard outcome measure for clinical trials of patients with follicular lymphoma, published in the British Journal of Hematology (online August 7, 2017;...
A...
08/14/2017
Journal of Clinical Pathways
Research in Review
08/10/2017
JCP Editors
Patients with myeloid malignancies who have vitamin D deficiency before undergoing allogeneic stem cell transplantation (alloSCT) are at a higher risk of relapse, according to recent research published in the Journal...
Patients with myeloid malignancies who have vitamin D deficiency before undergoing allogeneic stem cell transplantation (alloSCT) are at a higher risk of relapse, according to recent research published in the Journal...
...
08/10/2017
Journal of Clinical Pathways
Research in Review
08/09/2017
JCP Editors
Increasing the standard dose of an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of non-small cell lung cancer (NSCLC) improves objective response rates (ORR) by 9% with limited additional toxicity,...
Increasing the standard dose of an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of non-small cell lung cancer (NSCLC) improves objective response rates (ORR) by 9% with limited additional toxicity,...
...
08/09/2017
Journal of Clinical Pathways